Company & Sponsor Intelligence
Novo Nordisk A/S
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials6
Recruiting2
Completed4
Countries1
Therapeutic footprint
alzheimersout_of_scopestroke
Indexed studies
NCT04760626A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
out_of_scope · United StatesPHASE3
out_of_scope · United StatesPHASE3
NCT04777409A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
NCT07339423AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
out_of_scope · United StatesPHASE3
out_of_scope · United StatesPHASE3
NCT05514535A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
out_of_scope · United StatesPHASE3
out_of_scope · United StatesPHASE3
NCT03574597Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
stroke · United StatesPHASE3
stroke · United StatesPHASE3
NCT05567796A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
out_of_scope · United StatesPHASE3
out_of_scope · United StatesPHASE3
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →